Suspicion arises over sudden termination of Phase III clinical trials with clevudine

Published: 2009-04-28 07:00:00

Updated: 2009-04-28 07:00:00

Bukwang Pharm has questioned on Pharmasset’s April 20 announcement to voluntarily halt its Phase III QUASH studies of clevudine for the treatment of chronic hepatitis B (HBV) infection, amid reports that the two sides promised to have a meeting soon.

Under license from Bukwang, Pharmasset was developing the drug, but its phase III clinical trial (international, multicenter, randomized, doubl...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.